ClinicalTrials.gg
RecruitingNCT06837194Updated Feb 20, 2025

Washed Microbiota Transplantation Combined with Enteral Nutrition for Gastroptosis

An observational study in Gastroptosis and Malnutrition, sponsored by The Second Hospital of Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by The Second Hospital of Nanjing Medical University · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
24
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Malnutrition with a site in China — 20 open to participants now, 21 under way, 1 of them phase 3. Malnutrition · China.

Planned enrollment
27th of 27
24 · median 500
Started
2025
with 2 others
Observational
27 of 59
8 open now
Primary completion
2027-02
later than 10 of 20 live
Registered
49th of 59
by date
Lead sponsor
4 of 59
The Second Hospital of Nanjing Medical University

Among the 59 studies in Malnutrition with a site in China, this one is the 27th largest by planned enrollment of the 27 observational ones that give a count, is one of 3 that started in 2025, is one of 27 observational ones, reaches primary completion later than 10 of the 20 other live ones, and was the 49th registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

20 of the 59 studies in Malnutrition with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Malnutrition with a site in China, or all of them as a file.
02

Study summary

This is a observational study to explore the efficacy and safety of washed microbiota transplantation (WMT) combined with nutritional support for gastroptosis patients

03

Conditions studied

  • Gastroptosis
  • Malnutrition

Browse trials for

Keywords

  • washed microbiota transplantation
  • microbiota medicine
  • Gastroptosis
  • malnutrition
  • enteral nutrition
  • Transendoscopic Enteral Tubing
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients ≥18 years old with malnutrition and gastroptosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following inclusion criteria to enter the study:

    1. Clinically diagnosed with gastroptosis;
    2. Meets the diagnostic criteria for malnutrition (fulfilling any one of the following two criteria):

      • Weight loss (weight loss >5% within the last 6 months or >10% over more than 6 months);

        • Low (BMI \<18.5 kg/m² for individuals \<70 years old; BMI \<20 kg/m² for individuals ≥70 years old);
    3. Males aged ≥18 years and non-pregnant, non-lactating females aged ≥18 years;
    4. Willing to voluntarily sign a written form and agrees to follow medical advice for regular follow-up examinations and monitoring after the completion of treatment.

Exclusion criteria

Exclusion Criteria:

  • Subjects meeting any of the following exclusion criteria must be excluded from the study:

    1. Patients with severe depression, anxiety, or cognitive impairment that affects normal physician-patient communication and treatment planning;
    2. Patients with poor compliance who cannot accept treatment regimens such as nasogastric enteral nutrition;
    3. Anticipated survival time \<3 months;
    4. cardiovascular diseases, including heart failure ( Class III-IV), uncontrolled coronary artery disease, cardiomyopathy, arrhythmia, history of myocardial infarction, hemodynamic instability at enrollment, unstable vital signs, or anticipated risk events during treatment;
    5. Poor pulmonary function deemed by investigators to impact study treatment (e.g., acute exacerbation of or requirement for long-term oral/intravenous [excluding inhaled corticosteroids]);
    6. Active severe clinical infections (> Grade 2 per v5.0), including patients with intestinal fungal, viral, or tuberculosis infections;
    7. Inability to cooperate with intestinal tube placement or to intestinal tube placement;
    8. Use of medications affecting or modulating gut microbiota within the past 48 hours;
    9. Lack of legal capacity or restricted legal capacity;
    10. Hematologic disorders unsuitable for blood draw examinations;
    11. Other severe medical conditions deemed by investigators to preclude patient enrollment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
24 participants (estimated)
Target follow-up
24 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Observation Group

    Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive three doses of WMT and enteral nutrition for three months for gastroptosis.

06

What researchers measure

Primary outcomes

  1. The proportion of gastroptosis with degree relief after the procedure.

    Detailed evaluation content of efficacy rate of degree: The ultrasound examination was divided into three levels of light, medium and heavy according to the specific value of the middle gastric angle below Iliac spines are connected, defined as a reduction of at least 50% in value or a reduction of degree.

    Time frame: baseline, 12 weeks post transplantation

Secondary outcomes

  1. change of the third lumbar vertebrae skeletal muscle mass and height

    The third lumbar vertebrae skeletal muscle mass represents the sum of the cross-sectional areas of the skeletal muscles at the L3 level, including the psoas major, the erector spinae, the quadratus lumborum, the musculus transversus abdominis, the obliquus externus abdominis and the obliquus internus abdominis. Skeletal muscle mass and height will be combined to report the third lumbar vertebrae skeletal muscle mass index(L3 SMI) in cm\^2/m\^2.

    Time frame: baseline, 12 weeks post transplantation

  2. change of weight and height

    Weight and height will be combined to report BMI in kg/m\^2.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation

  3. change of the Gastrointestinal Symptom Rating Scale(GSRS)

    GSRS is a 13-item test to make a comprehensive assessment of common gastrointestinal symptom and each item receives a value from 0 to 3, with higher value indicating worse gastrointestinal condition.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation

  4. The extent of change observed in Gastroparesis Cardinal Symptom Index(GCSI)of participants

    The GCSI consists of nine items and three subscales to measure symptoms related to gastroparesis. The nausea/vomiting subscale consists of the following three items: nausea, retching, and vomiting. The postprandial fullness/early satiety subscale consists of the following four items: stomach fullness, inability to finish a normal-sized meal, feeling excessively full after meals, and loss of appetite.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation

  5. The results of gastric fitted emptying rate data for 2 hours or 4 hours in the gastric emptying experiment with nuclide imaging

    Time frame: baseline, 12 weeks post transplantation

  6. change of the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L)

    EQ-5D-5L is a 5-dimension questionnaire measuring health state and each dimension represents the level from 1 to 5, with higher level indicating worse health state.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation

  7. change of the Pittsburgh Sleep Quality Index (PSQI)

    PSQI is a self-rated questionnaire which assesses sleep quality over a 1-month time interval. Nineteen items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for seven components yields one global score, with higher score indicating worse sleep quality.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation

  8. change of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

    FACIT-Fatigue is a 13-item test measuring fatigue and each item receives a value from 0 to 4, with higher value indicating worse fatigue state.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation

  9. The extent of change observed in gastrointestinal ultrasound (GIUS) of participants

    The half gastric emptying time will be evaluated by GIUS.

    Time frame: baseline, 12 weeks post transplantation

  10. The extent of change observed in transcranial Doppler (TCD) of participants

    TCD was used to evaluate the degree of continuity of echo in the nucleus suture in patients, and echoic discontinuity represented the possibility of anxiety and depression.

    Time frame: baseline, 12 weeks post transplantation

  11. change of the Hamilton Anxiety Scale(HAMA)

    Hamilton Anxiety Scale is a 14-item test measuring anxiety and each item receives a value from 0 to 4, with higher value indicating worse anxiety state.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation

  12. change of the Hamilton Depression Scale(HAMD)

    Hamilton Depression Scale is a 17-item test measuring depression and each item receives a value from 0 to 4, with higher value indicating worse depression state.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation

  13. change of insulin-like growth factor I(IGF-I)

    Blood is tested for Insulin-like growth factor I.

    Time frame: baseline, 12 weeks post transplantation

  14. change of albumin and Prealbumin

    Blood is tested for albumin and Prealbumin.

    Time frame: baseline, 12 weeks post transplantation

  15. change of cytokine

    Blood is tested for IL-1β、IL-2、IL-4、IL-5、IL-6、IL-8、IL-10、IL-12p70、IL-17、TNF-α、IFN-γ、IFN-α.

    Time frame: baseline, 12 weeks post transplantation

  16. The changes in gut microbiota composition and metabolites before and after treatment

    The 16s-RNA or meta-analysis of gut microbiota will be used.

    Time frame: baseline, 12 weeks post transplantation

  17. the incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0

    The severity of AE was graded as mild (grade 1), moderate (grade 2), severe/disabling (grade 3), life threatening (grade 4), and death (grade 5). All AE were divided in definitely, probably and possibly related to treatment. The treatment-related AE we focused on included microbiota-related AEs (e.g., infection, diarrhea, abdominal pain, etc.) and route of delivery related AEs (e.g., nausea, vomiting, etc.).

    Time frame: 12 weeks post transplantation

07

Study locations

1 of 1 sites recruiting
  • Department of Microbiota Medicine & Medical Centre for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jangsu 210000, China
    Recruiting
08

References and documents

Publications

  • Zhang F, Cui B, He X, Nie Y, Wu K, Fan D; FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018 May;9(5):462-473. doi: 10.1007/s13238-018-0541-8. Epub 2018 Apr 24. PubMed 29691757 ↗
  • Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, Li P, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Colonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota. Endosc Int Open. 2016 Jun;4(6):E610-3. doi: 10.1055/s-0042-105205. Epub 2016 Apr 28. PubMed 27556065 ↗
  • Quince C, Ijaz UZ, Loman N, Eren AM, Saulnier D, Russell J, Haig SJ, Calus ST, Quick J, Barclay A, Bertz M, Blaut M, Hansen R, McGrogan P, Russell RK, Edwards CA, Gerasimidis K. Extensive Modulation of the Fecal Metagenome in Children With Crohn's Disease During Exclusive Enteral Nutrition. Am J Gastroenterol. 2015 Dec;110(12):1718-29; quiz 1730. doi: 10.1038/ajg.2015.357. Epub 2015 Nov 3. PubMed 26526081 ↗
  • Xiang L, Yu Y, Ding X, Zhang H, Wen Q, Cui B, Zhang F. Exclusive Enteral Nutrition Plus Immediate vs. Delayed Washed Microbiota Transplantation in Crohn's Disease With Malnutrition: A Randomized Pilot Study. Front Med (Lausanne). 2021 Oct 22;8:666062. doi: 10.3389/fmed.2021.666062. eCollection 2021. PubMed 34746161 ↗
  • Fernandes ND, Murphy SA. Gastroptosis: An Uncommon Cause for a Deep Nasogastric Tube. Clin Gastroenterol Hepatol. 2021 Jun;19(6):A23. doi: 10.1016/j.cgh.2020.04.016. Epub 2020 Apr 11. No abstract available. PubMed 32289543 ↗
  • Xu LC, Garcia JC. Gastroptosis in a young woman. Gastrointest Endosc. 2024 Mar;99(3):454-455. doi: 10.1016/j.gie.2023.10.006. Epub 2023 Oct 5. No abstract available. PubMed 37804872 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 175 non-industry observational studies under Malnutrition, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 24 months is close to that.

Counting every sponsor, half of 187 studies reached it within 21 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 20, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Feb 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06837194
Lead sponsor
The Second Hospital of Nanjing Medical University
Responsible party
Faming Zhang (Professor, Gastroenterology, The Second Hospital of Nanjing Medical University) — Principal investigator
First posted
Feb 20, 2025
Start date
Feb 1, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Feb 20, 2025

Study contacts

Faming Zhang, PhD
Contact
fzhang@njmu.edu.cn
086-025-58509883
Bota Cui, PhD
Contact
cuibota@njmu.edu.cn
086-025-58509884
Faming Zhang
principal investigator · The Second Hospital of Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion